Research programme: analgesics - CeNeS/Endo

Drug Profile

Research programme: analgesics - CeNeS/Endo

Alternative Names: Analgesics research programme - CeNeS/Endo

Latest Information Update: 21 Mar 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CeNeS Pharmaceuticals; Endo Pharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 11 Sep 2002 Discontinued - Preclinical for Pain in USA (unspecified route)
  • 31 Dec 2001 Endo has been merged with and into Endo Pharmaceuticals
  • 16 Feb 2001 Cambridge NeuroScience is now called CeNeS Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top